Supporting Innovation through Regulation and Science

Similar documents
Horizon Societal Challenge 1: Health, demographic change and wellbeing. Jeremy Bray DG Research & Innovation European Commission

Health Innovations in Horizon 2020: the framework programme for research and innovation ( )

EMA experience with the review of digital technology proposals in medicine development programmes

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation

EU s Innovative Medical Technology and EMA s Measures

Health & Social Care Industrial Innovation

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint

Translational scientist competency profile

IMI Revolutionising Europe s Pharmaceutical Industry. IMI Matters!

FDA Centers of Excellence in Regulatory and Information Sciences

Security and Risk Assessment in GDPR: from policy to implementation

Justice Select Committee: Inquiry on EU Data Protection Framework Proposals

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships

Fifth Framework Programme for Research, Technological Development and Demonstration Quality of Life and Management of Living Resources

Strategic Plan Public engagement with research

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

Expectations around Impact in Horizon 2020

Research Development Request - Profile Template. European Commission

Robotics: from FP7 to Horizon Libor Král, Head of Unit Unit A2 - Robotics DG Communication Networks, Content and Technology European Commission

Overview on Medicines Regulation: regulatory cooperation and harmonization in focus

CHINA MED DEVICE. China Medtech Will Continue Its Double Digit Growth in Years to Come

Implementation of Systems Medicine across Europe

Before I talk through the strategy itself, I want to tell you more about why

Promoting Patient and Researcher Engagement with Distributed Data Research Networks through Hurdle Free Tools

HDR UK & Digital Innovation Hubs Introduction. 22 nd November 2018

Webinar IMI2 Call 13 Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice

SME INSTRUMENT & FAST TRACK TO INNOVATION

NIHR ROADSHOW FOR MEDTECH SMES

Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

Twenty-Thirty Health care Scenarios - exploring potential changes in health care in England over the next 20 years

CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes

Infoday Madrid 19 October 2017 NMBP Programme OPEN INNOVATION TEST BEDS Calls 2018/2019

Medical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade

NMP & Health H calls - short overview

Andalusian Agency for Health Technology Assessment (AETSA)

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei

Changing landscape - changing paradigms

The New Delhi Communiqué

IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?

Systems Approaches to Health and Wellbeing in the Changing Urban Environment

Doing, supporting and using public health research. The Public Health England strategy for research, development and innovation

Sustainable Data for Sustainable Development

Issues in Emerging Health Technologies Bulletin Process

NHS Next Stage Review: Innovation

Your Content Your Way

CDRH INNOVATION INITIATIVE. February 2011 Center for Devices and Radiological Health U.S. Food and Drug Administration

What s going on at the MRC

Magnus Steigedal Director NTNU Health NTNU

Draft Plan of Action Chair's Text Status 3 May 2008

EU Advanced Manufacturing Funding through Horizon Key Enabling Technologies. Dr Liam Brown. Horizon 2020 National Delegate Enterprise Ireland

Evidence Standards and AI

Where the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes

Horizon 2020 Towards a Common Strategic Framework for EU Research and Innovation Funding

Framework Programme 7

Evidence for Effectiveness

E5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006

The Role of the EU Regions in Supporting Robotics

Strategic Foresight Initiative 2011 Summary Briefing

Digital Health Startups A FirstWord ExpertViews Dossier Report

Higher Education Contribution to Health Science Innovation

EU RESEARCH Nanotechnologies and Advanced Materials and beyond. Safe Nanotechnology. Dr. Georgios Katalagarianakis European Commission

Future and Emerging Technologies. Ales Fiala, Head of Unit C2 European Commission - DG CONNECT Directorate C - Excellence in Science

Kate Pretty Lecture Thursday 8 March Pascal Soriot, CEO AstraZeneca. What Science Can Do The Cambridge Cluster at a Pivot Point

Synergies and Complementarities with EU Research & Innovation Policy

The value of innovative pharmaceuticals and the potential for Vietnam. Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016

Article 117 A Notified Body perspective, advice on how and when to engage notified bodies

EU Research Integrity Initiative

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Fact Sheet IP specificities in research for the benefit of SMEs

Comprehensive Research Services

Integrated Scientific Advice Workshop: ISPOR Glasgow

Ministry of Justice: Call for Evidence on EU Data Protection Proposals

International Cooperation in Horizon 2020

Innovation and the Changing Practice of Medicine

Powered by: Norway for Life Science. Photo cover: Christopher Olssøn Design: Fete typer

ACTION PLAN. Photo: Viktor Hanacek/Picjumbo

peace of mind For from development to commercial supply

Ministerial Conference on Nuclear Science and Technology: Addressing Current and Emerging Challenges Vienna, November 2018

Education and Culture

Driving Innovation. Connect and Catalyse. Medicines and Healthcare the Global perspective (+10 years) Zahid Latif

SHTG primary submission process

The new deal of data in the data-driven person centric-care

Software as a Medical Device (SaMD)

Pharmacovigilance Inspection Metrics Report

Maximising Impact Through Engaged Research. Sarah Bowman Trinity College Dublin Campus Engage Convenor

Leader in Pharmaceutical Films

COM C. Rozwell

Innovation Crossover Research Life Sciences/Biomedical Health Informatics. Distribution Statement A: Approved for Public Release

UNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015

Green Paper - From Challenges to Opportunities: Towards a Common Strategic Framework. for EU Research and Innovation Funding

topics topics. The societal challenge 'Health, demographic change and well-being' Amalia-Irina Vlad MD PhD Health Directorate DG RTD

Life sciences road map pathway to a national strategy

Impact Case Study Template. Guidance Document

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

the SPD company Dr Clive Simon, Principal, The SPD Company.

Cultural Evolution Is the future in our own hands?

Transcription:

Supporting Innovation through Regulation and Science Larry O Dwyer, Scientific Affairs Manager PEARRL Regulatory Science Symposium 21 st June 2017, School of Pharmacy, UCC

Overview of Presentation Drivers for innovation Some HPRA activities to support innovation Education and Outreach Horizon-scanning Classification Innovation Office 15/06/2017 2

Drivers for Innovation

Population Demographics are Changing Source: Aging with Tech Support McKinsey and Company Sept 2016 15/06/2017 4

Treatment Needs are Changing Cancer Ageing Population Long-Term Chronic Diseases Cardiovascular Disease Respiratory Disease Cancer Diabetes 15/06/2017 5

Treatment Needs are Changing Cancer Ageing Population Long-Term Chronic Diseases Cardiovascular Disease Respiratory Disease Cancer Diabetes 15/06/2017 6

Patients Knowledge and Expectations are Increasing Source: Future of Ireland III, Innovation Matters www.futureofireland.ie 15/06/2017 7

15/06/2017 8 The Life-Sciences Sector is Changing More collaboration between industry and academia and partnerships between companies Looking for newer R&D models New technologies providing opportunities

New Medicines in the EU 2010-2012 Proportion of New Medicines (%) 28% 59% 21% 28% 27% 13% 17% Originator MAH 0 7% 0 Large Company Intermediate-sized Company SME Academia/public bodies / PPPs Private Collaborations Significant % of new medicines originated from SMEs and Academia Source: H. Lincker et al Nature Reviews Drug Discovery Vol 13 pp 92-93 (2014) 15/06/2017 9

Sources of Innovation 15/06/2017 10

Percentage of Global R&D Spending in 2016, by industry Source: statistica.com 15/06/2017 11

Clinical Trials 15/06/2017 12

Clinical Trials Use of Selection Biomarkers Source: Clinical Development Success Rates 2006-2015, BIO, Biomedtracker, Amplion 15/06/2017 13

Examples of Novel Technologies / Product Types 3D Printing Robotics Drug-Device Combinations 15/06/2017 14

HPRA Activities to Support Innovation

Supporting Innovation A key Strategic objective 15/06/2017 16

15/06/2017 17 Examples of Some Recent Initiatives to Support Innovation National Scientific Advice Outreach Programme Involvement in Regulatory Science Ireland Horizon Scanning Involvement in PEARRL Supporting Innovation Innovation Office

Education and Outreach HPRA contributes to undergraduate courses and taught Masters in relevant disciplines Focus of outreach includes third level institutes, research and technology centres, SMEs Aim is to understand needs of researchers, agree engagement methods, increase awareness of the role and activities of HPRA 15/06/2017 18

15/06/2017 19 Horizon-Scanning Using internal and external sources of intelligence Aims are to inform need for: future regulatory changes, enhanced outreach, development of additional expertise, new ways of working

15/06/2017 20 Classification Important to identify the regulatory framework that will apply to an innovation at an early stage of development HPRA has a classification procedure for borderline products: medicines / medical devices / cosmetics / non-medicinal (e.g. foods) Details available on HPRA website Borderlines may be subject to change with the impact of legislation, e.g., new medical devices legislation, EU review of botanicals

15/06/2017 21 HPRA Innovation Office Launched in Nov 2016 An initial point of contact for innovators to submit queries in relation to innovative products and technologies within the HPRA s remit Queries can be submitted at any stage of development including initial research HPRA is also part of the EU Innovation Network

Submissions to the Innovation Office Query Submission via a dedicated online form or a dedicated email address Request for general guidance on regulatory / scientific issues HPRA Review Response Queries will be reviewed by relevant HPRA experts Written response will generally be sent within 20 working days Response may recommend more detailed scientific advice May propose meeting or further interaction as development proceeds 15/06/2017 22

15/06/2017 23 Topics Addressed in Innovation Office Queries 5% 5% 5% 9% Medical Devices Medicines 43% Drug / Device Combinations 33% Diagnostics Cosmetics Other

15/06/2017 24 Origin of Innovation Office Queries 4% 9% 9% 14% SME 32% 32% Academia Life Sciences Industry Individuals Consortium Others / Unknown

15/06/2017 25

15/06/2017 26 Benefits from Supporting Innovation Support the dynamic innovative environment within Ireland Strengthen links between HPRA and Innovators Clarify regulatory requirements at an early stage and help to avoid issues at later stages of development Inform the future development of the HPRA Ensure that the HPRA is well positioned to take a lead role in relation to the regulation of innovative products and technologies at a European and international level Patients will benefit via the facilitation of more timely access to innovative health products

Thank you Contact the innovation office via our website: www.hpra.ie Email: innovationoffice@hpra.ie 15/06/2017 27